Pipeline

iOmx is advancing a pipeline of promising drug candidates that have the potential to address cancers that are resistant to current therapies, covering the most prevalent solid tumor indications.

OMX-0407 – first-in-class spectrum-selective kinase inhibitor– in phase Ib
OMX-0407 is an orally available, first-in-class spectrum-selective inhibitor of SIK (salt-inducible kinase) and other oncology-relevant tyrosine kinases. The mode of action of OMX 0407 combines immune sensitization and modulation of the tumor microenvironment with direct tumor cell cycle arrest, thereby driving tumor eradication.
OMX-0407 has strong monotherapy potential in multiple solid tumor indications (e.g. RCC, sqNSCLC, UBC, CRC, head & neck cancer and angiosarcoma) and is currently in clinical phase Ib (monotherapy) development towards clinical proof-of-concept in two priority indications (RCC and angiosarcoma).

IOMX-0675 – dual-targeting antibody against LILRB1 and LILRB2 – CTA approved
iOmx´s proprietary, dual-targeting, best-in-class antibody IOMX-0675 addresses a key immune-regulatory receptor family expressed on myeloid cells and other lymphoid immune cells, the LILR family. This receptor superfamily contains both, immune-suppressive as well as immune-activating receptors, displaying very high structural homology. IOMX-0675 is targeting LILRB1 and LILRB2, the two most potent immunosuppressive members of this family. IOMX-0675 is a fully human, cross-specific, high-affinity ligand-blocking antibody that simultaneously neutralizes both, LILRB1 and LILRB2, while sparing LILRA1 and LILRA3, two closely related immune-activating family members. The highly differentiated selectivity profile of IOMX-0675 unleashes the full anti-tumor potential by re-activating innate and adaptive immunity, as exhibited by potent reprogramming of the immunosuppressive myeloid compartment and restoration of cytotoxic T cell activity in the tumor microenvironment. IOMX-0675, an antibody with best-in-class potential in an evolving target class with cumulating clinical validation, has successfully advanced through IND-enabling studies, with a CTA approved.

IOMX-0235 – Fc-enhanced antibody against CCR9 – clinical lead selected
IOMX-0235 is a humanized, Fc-enhanced, and cynomolgus monkey cross-reactive monoclonal antibody for the treatment of inflammatory bowel disease (Ulcerative Colitis & Crohn´s Disease). It is Fc-engineered to efficiently deplete CCR9-positive cells with sub-nM EC50, both in vitro and in vivo – ready to enter IND-enabling development.

Discovery Programs – Bispecifics & T cell engagers – in lead optimization
In addition, iOmx is driving several discovery programs to add to its pipeline of next-generation immuno-oncology drugs, e.g., a tri-functional bispecific antibody synergistically blocking multiple immuno-suppressive pathways as well as several T cell engager programs against novel undisclosed tumor-specific targets.

To learn more about potential partnering opportunities, please contact us at: info@iomx.com